EC Number |
Inhibitors |
Structure |
---|
3.1.1.79 | (3,4-dihydro-1H-isoquinolin-2-yl)-carbamic acid 4-tert-butoxycarbonylamino-phenyl ester |
IC50: 3 nM |
|
3.1.1.79 | (5-chloro-2-[([6-[4-(trifluoromethyl)phenoxy]pyridin-3-yl]carbonyl)amino]phenyl)boronic acid |
potent HSL inhibitor with a significantly reduced bioactivation potential. Oral administration of compound exhibit an antilipolytic effect on rats at 3 mg/kg |
|
3.1.1.79 | (5-fluoro-2-[([6-[4-(trifluoromethyl)phenoxy]pyridin-3-yl]carbonyl)amino]phenyl)boronic acid |
potent inhibitor, in vitro and in cell with high selectivity for cholinesterases AChE and BuChE. The compound exhibits antilipolytic effect in rats at 1 mg/kg p.o. and does not show bioactivation |
|
3.1.1.79 | (S)-4-isopropyl-3-methyl-2-[3-methylpiperidine-1-carbonyl]isoxazol-5[2H]-one |
- |
|
3.1.1.79 | 2-methoxyphenyl 3,4-dihydroisoquinolin-2(1H)-ylcarbamate |
IC50: 6400 nM |
|
3.1.1.79 | 2-propanol |
80-90% inhibition |
|
3.1.1.79 | 3-(3,5-dichlorophenyl)-N,N-dimethyl-5-(methylsulfanyl)-1H-1,2,4-triazole-1-carboxamide |
- |
|
3.1.1.79 | 3-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-5-ethoxy-1,3,4-oxadiazol-2(3H)-one |
- |
|
3.1.1.79 | 3-(4-chlorophenyl)-N,N-dimethyl-5-(methylsulfanyl)-1H-1,2,4-triazole-1-carboxamide |
- |
|
3.1.1.79 | 4-(acetylamino)phenyl morpholin-4-ylcarbamate |
- |
|